<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
/ X / Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarterly period ended June 30, 2000 or
/ / Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from _____________ to _____________
Commission File Number: 00024889
CELL PATHWAYS, INC.
(Exact name of registrant as specified in its charter)
Delaware 23-2969600
------------------------------------------ ---------------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification Number)
702 Electronic Drive Horsham, Pennsylvania 19044
------------------------------------------ ---------------------------
(Address of Principal Executive Office) (Zip Code)
(215) 706-3800
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
------- ------
At July 31, 2000 there were 27,843,456 shares of Common Stock, par value $0.01
per share, outstanding.
<PAGE> 2
CELL PATHWAYS, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
INDEX TO FORM 10-Q
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2000
<TABLE>
<CAPTION>
PART 1 FINANCIAL INFORMATION (UNAUDITED) Page
------ --------------------------------- -------
<S> <C>
Item 1 Financial Statements:
Condensed Consolidated Balance Sheets as of June 30, 2000
and December 31, 1999 3
Condensed Consolidated Statements of Operations for the three and six months
ended June 30, 2000 and 1999 and for the period from inception (August 10,
1990) to June 30, 2000 4
Condensed Consolidated Statements of Cash Flows for the three and six months
ended June 30, 2000 and 1999 and for the period from inception (August 10,
1990) to June 30, 2000 5 - 6
Notes to Condensed Consolidated Financial Statements 7 - 8
Item 2 Management's Discussion and Analysis of Financial Condition and
Results of Operations 9 - 11
Item 3 Quantitative and Qualitative Disclosures about Market Risk 12
PART II OTHER INFORMATION
Item 1 Legal Proceedings 13
Item 2 Change in Securities and Use of Proceeds 13
Item 4 Submission of Matters to a Vote of Security Holders 13
Item 6 Exhibits and Reports on Form 8-K 14
Signatures 15
</TABLE>
2
<PAGE> 3
CELL PATHWAYS, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
JUNE 30, DECEMBER 31,
2000 1999
------------- ------------
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 35,467,645 $ 32,013,118
Prepaid expenses and other 1,596,815 875,433
------------- ------------
Total current assets 37,064,460 32,888,551
EQUIPMENT, FURNITURE and LEASEHOLD IMPROVEMENTS, NET 1,512,614 1,519,655
OTHER ASSETS 895,584 870,765
------------- ------------
$ 39,472,658 $ 35,278,971
============= ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Current installments of obligation under capital lease $ 111,315 $ 146,260
Accounts payable 1,375,593 1,510,569
Other accrued liabilities 2,478,995 2,125,483
------------- ------------
Total current liabilities 3,965,903 3,782,312
------------- ------------
Obligation under capital lease, excluding current installments
-- 33,917
------------- ------------
STOCKHOLDERS' EQUITY :
Preferred Stock, $.01 par value, 10,000,000 and 5,000,000 shares
authorized, none issued and outstanding -- --
Common Stock, $.01 par value, 150,000,000 and 70,000,000 shares 275,978 261,059
authorized; 27,597,786 and 26,105,894 shares issued and
outstanding
Additional paid-in capital 113,921,954 96,202,177
Stock subscription receivable from issuance of Common Stock (37,000) (37,000)
Deficit accumulated during the development stage (78,654,177) (64,963,494)
------------- ------------
Total stockholders' equity 35,506,755 31,462,742
------------- ------------
$ 39,472,658 $ 35,278,971
============= ============
</TABLE>
The accompanying notes to the condensed consolidated financial statements are an
integral part of these statements.
3
<PAGE> 4
CELL PATHWAYS, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
PERIOD FROM
INCEPTION
THREE MONTHS ENDED SIX MONTHS ENDED (AUGUST 10,
JUNE 30, JUNE 30, 1990) TO
---------------------------- ------------------------------ -------------
2000 1999 2000 1999 JUNE 30, 2000
----------- ----------- ------------ ------------ -------------
<S> <C> <C> <C> <C> <C>
EXPENSES:
Research and development $ 5,237,800 $ 3,590,342 $ 10,617,762 $ 8,118,235 $ 64,000,950
General and administrative 2,455,667 1,067,752 4,086,878 2,212,296 17,745,085
Provision for redemption of the
Redeemable Preferred Stock -- -- -- -- 1,017,000
----------- ----------- ------------ ------------ ------------
Total expenses 7,693,467 4,658,094 14,704,640 10,330,531 82,763,035
INTEREST INCOME 539,756 325,383 1,013,957 693,229 4,108,858
----------- ----------- ------------ ------------ ------------
NET LOSS $(7,153,711) $(4,332,711) $(13,690,683) $ (9,637,302) $(78,654,177)
=========== =========== ============ ============ ============
Basic and diluted net loss per Common Share $ (0.26) $ (0.18) $ (0.50) $ (0.40)
=========== =========== ============ ============
Shares used in computing basic and
diluted net loss per Common Share 27,569,399 24,340,270 27,125,820 24,324,887
=========== =========== ============ ============
</TABLE>
The accompanying notes to the condensed consolidated financial statements are an
integral part of these statements.
4
<PAGE> 5
CELL PATHWAYS, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
PERIOD FROM
SIX MONTHS ENDED INCEPTION
JUNE 30, (AUGUST 10,
------------------------------ 1990) TO
2000 1999 JUNE 30, 2000
------------ ------------ -------------
<S> <C> <C> <C>
OPERATING ACTIVITIES:
Net loss $(13,690,683) $ (9,637,302) $ (78,654,177)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation expense and amortization 387,738 269,224 1,308,304
Issuance of Common Stock for services rendered -- -- 48,578
Issuance of Common Stock options for
services rendered 483,654 -- 594,018
Provision for redemption of Redeemable
Preferred Stock -- -- 1,017,387
Write-off of deferred offering costs -- -- 469,515
Other -- -- 68,399
(Increase) decrease in prepaid expenses and (1,195,335)
other current assets (638,528) 15,776
(Increase) decrease in other assets (65,764) 77,972 (145,652)
Increase (decrease) in accounts payable and
accrued liabilities 218,536 (1,398,903) 1,233,597
------------ ------------ -------------
Net cash flows used in operating activities (13,305,047) (10,673,233) (75,255,366)
------------ ------------ -------------
INVESTING ACTIVITIES:
Purchase of equipment, furniture and
leasehold improvements (380,697) (300,862) (5,299,067)
Sale of leasehold improvements -- -- 3,000,000
Cash paid for deposits (24,673) -- (75,440)
------------ ------------ -------------
Net cash flows used in investing activities (405,370) (300,862) (2,374,507)
------------ ------------ -------------
FINANCING ACTIVITIES:
Proceeds from the issuance of Common Stock,
net of related offering costs -- -- 13,579,145
Proceeds from the exercise of warrants to
purchase Common Stock 14,464,494 -- 14,464,494
Proceeds from the issuance of Common Stock
under the Employee Stock Purchase Plan 159,685 -- 330,805
Proceeds from issuance of Convertible
Preferred Stock, net of related offering costs -- -- 47,185,046
Proceeds from the transaction with Tseng
Labs, Inc. -- -- 27,966,372
Proceeds from exercise of Series E, F and G
warrants to purchase stock 702,050 439,205 2,223,893
Proceeds from the exercise of options to
purchase Common Stock 1,924,813 275,941 2,648,235
Decrease in shareholder receivable -- -- 23,626
Redemption of Redeemable Preferred Stock -- -- (546,051)
Proceeds from bridge loan -- -- 791,000
Partner cash contributions -- -- 5,312,355
Increase in restricted cash (17,236) -- (657,346)
Principal payments under capital lease
obligations (68,862) (61,110) (224,056)
Proceeds from borrowings -- -- 150,000
Repayment of borrowings -- -- (150,000)
------------ ------------ -------------
Net cash flows provided by financing activities 17,164,944 654,036 113,097,518
------------ ------------ -------------
Net increase (decrease) in cash and cash equivalents 3,454,527 (10,320,059) 35,467,645
CASH AND CASH EQUIVALENTS, beginning of period 32,013,118 37,232,404 --
------------ ------------ -------------
CASH AND CASH EQUIVALENTS, end of period $ 35,467,645 $ 26,912,345 $ 35,467,645
============ ============ =============
</TABLE>
The accompanying notes to the condensed consolidated financial statements are an
integral part of these statements.
5
<PAGE> 6
CELL PATHWAYS, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(CONTINUED)
(UNAUDITED)
<TABLE>
<CAPTION>
PERIOD FROM
SIX MONTHS ENDED INCEPTION
JUNE 30, (AUGUST 10,
------------------------- 1990) TO
2000 1999 JUNE 30, 2000
---------- ---------- -------------
<S> <C> <C> <C>
SUPPLEMENTAL DISCLOSURES OF NONCASH
FINANCING ACTIVITIES:
Accrual of leasehold improvements payable $ -- $ -- $ 848,000
========== ========== ===========
Accrual of deferred offering costs $ -- $ -- $ 441,375
========== ========== ===========
Conversion of partners' investment to $ -- $ -- $ 5,312,355
========== ========== ===========
Preferred Stock
Conversion of bridge loan to Convertible
Preferred Stock $ -- $ -- $ 791,000
========== ========== ===========
Conversion of Convertible Preferred Stock
for Common Stock $ -- $ -- $53,766,991
========== ========== ===========
Issuance of Convertible Preferred Stock to
investment advisors $ -- $ -- $ 540,742
========== ========== ===========
Issuance of Common Stock as payment of
management bonus $ -- $ -- $ 59,200
========== ========== ===========
Redemption of Redeemable Preferred Stock for
Common Stock $ -- $ -- $ 545,949
========== ========== ===========
Sale of Common Stock in exchange for stock
subscription receivable $ -- $ -- $ 37,000
========== ========== ===========
Sale of Convertible Preferred Stock in
exchange for stock subscription receivable $ -- $ -- $ 23,626
========== ========== ===========
Issuance of Common Stock as payment for
accounts payable $ -- $ -- $ 48,578
========== ========== ===========
</TABLE>
The accompanying notes to the condensed consolidated financial statements are an
integral part of these statements.
6
<PAGE> 7
CELL PATHWAYS, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2000
(UNAUDITED)
1. ORGANIZATION AND BASIS OF PRESENTATION
Organization
Cell Pathways, Inc. was incorporated in Delaware in July 1998 as a
subsidiary of, and as of November 3, 1998 successor to, a Delaware corporation
of the same name. As the context requires, "Company" is used herein to signify
the successor and/or the predecessor corporations.
The Company is a pharmaceutical company focused on the research,
development and future commercialization of products to prevent and treat
cancer. The Company is in the development stage and has not generated any
product revenues to date, nor is there any assurance of any future product
revenues. The Company's intended products are subject to long development cycles
and there is no assurance the Company will be able to successfully develop,
manufacture, obtain regulatory approval for or market its products. During the
period required to develop its products, the Company plans to continue to
finance operations through debt and equity financings, corporate alliances or
through combinations thereof. There is no assurance, however, that such
additional funding will be available on terms acceptable to the Company, if at
all. The Company will continue to be considered in the development stage until
such time as it generates significant revenues from its principal operations. As
of June 30, 2000, the Company had a deficit accumulated during the developmental
stage of $78,654,177.
On November 3, 1998, the Company completed a financing through the
acquisition of Tseng Labs, Inc. ("Tseng") (a publicly held shell company) in
which the Company issued to Tseng stockholders approximately 5.5 million shares
of the Company's Common Stock and received net proceeds of approximately $26.4
million. The accompanying consolidated financial statements include the accounts
of the Company from inception (August 10, 1990) and the accounts of Tseng after
November 3, 1998.
Basis of Presentation
The unaudited condensed consolidated financial statements as of June
30, 2000 and for the three and six months ended June 30, 2000 and 1999, are
unaudited but include all adjustments (consisting only of normal recurring
adjustments) which, in the opinion of management, are necessary to state fairly
the financial information set forth therein in accordance with generally
accepted accounting principles. The interim results may not be indicative of the
results that may be expected for the year. These financial statements should be
read in conjunction with the audited consolidated financial statements for the
year ended December 31, 1999 included in the Company's annual report on Form
10-K filed with the Securities and Exchange Commission.
2. BASIC AND DILUTED NET LOSS PER COMMON SHARE
The Company provides basic and diluted net loss per Common share
pursuant to Statement of Financial Accounting Standards ("SFAS") No. 128,
"Earnings Per Share." SFAS No. 128 requires dual presentation of basic and
diluted net loss per Common share. "Basic" net loss per Common share equals net
loss divided by the weighted average Common shares outstanding during the
period. "Diluted" net loss per Common share equals net loss divided by the sum
of the weighted average Common shares outstanding during the period plus Common
Stock equivalents. The Company's basic and diluted net loss per share amounts
are the same since the assumed exercise of stock options and warrants are
anti-dilutive. The amount of Common Stock equivalents excluded from the
calculation are options and warrants to purchase 2,561,299 and 2,043,408 shares
of Common Stock as of June 30, 2000 and 1999, respectively.
7
<PAGE> 8
3. LITIGATION
In February and March of 1999, five stockholder class actions were
filed against the Company and certain of its officers and directors in the
United States District Court for the Eastern District of Pennsylvania seeking
unspecified damages on behalf of various classes of persons, including all
persons who purchased Company Common Stock during certain periods in 1998 and
1999. The complaints alleged that the Company made false and misleading
statements about the efficacy and near-term commercialization of the Company's
lead drug candidate, which had the effect of artificially inflating the price of
the Company's Common Stock. These actions were consolidated into one action in
April 1999, and a consolidated amended complaint was filed in late June 1999
asserting a class period extending from October 7, 1998 to February 2, 1999. The
litigation is at a very preliminary stage. The Company believes that the
allegations are without merit and intends to vigorously defend the litigation.
8
<PAGE> 9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Cell Pathways, Inc. was incorporated in Delaware in July 1998 as a
subsidiary of, and, as of November 3, 1998, the successor to, a Delaware
corporation of the same name. As the context requires, the "Company" or "CPI" is
used herein to signify the successor and/or the predecessor corporations
The business of the Company is subject to substantial risks and
uncertainties. These risks and uncertainties relate to, among other factors, the
absence of product sales; the absence of approved products; the history of
operating losses; the early stage of development; the costs, delays and
uncertainties inherent in basic pharmaceutical research, drug development,
clinical trials and the regulatory approval process, with respect to both the
Company's current product candidates and its future product candidates, if any;
dependence on development of Aptosyn(TM) (exisulind); the limitations on, or
absence of, the predictive value of data obtained in laboratory tests, animal
models and human clinical trials when planning additional steps in product
development; the uncertainty of obtaining regulatory approval of the New Drug
Application ("NDA") submitted for the Company's first product candidate,
Aptosyn(TM), for familial adenomatous polyposis ("FAP") (a rare disease that
puts those afflicted at high risk of developing colon cancer), whether in
connection with the adequacy of the data generated in the clinical trials of
Aptosyn(TM) or otherwise; the uncertainty of whether the Company's second
product candidate will demonstrate safety or effectiveness or that it will ever
be submitted for regulatory approval; the uncertainty of the effect of any
product approval, if achieved, on the market price of the Common Stock; the
timing and scope of any approval which might be received for any compound for
any indication in the future; acceptance by providers of healthcare
reimbursement; the validity, scope and enforceability of patents; the actions of
competitors; dependence upon third parties; product liability; and the need for
further financing. These and other risks are detailed in the Company's reports
filed from time to time under the Securities Act of 1933 and/or the Securities
Exchange Act of 1934, including the sections entitled "Business," "Risk
Factors," "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and "Other Events" in the Company's reports on Form 10-K
for the year ended December 31, 1999, Form 8-K filed in August 1999, Form S-3
filed in December 1999 and including any future reports and other filings.
Current and prospective investors are encouraged to read these filings as they
are made from time to time. They are available over the Internet from the SEC in
its EDGAR database or directly from the Company. Certain statements made in this
document or in those filings, and oral statements which may be made about them,
constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements are
those which express plan, anticipation, intent, contingency or future
development and/or otherwise are not statements of historical fact. These
statements are subject to risks and uncertainties, known and unknown, such as
the risks described above, which could cause actual results and developments to
differ materially from those expressed or implied in such statements. Given the
uncertainties affecting development stage pharmaceutical enterprises like the
Company, current and prospective investors are cautioned not to place undue
reliance on any such forward-looking statements, any of which may turn out to be
wrong due to inaccurate assumptions, unknown risks, uncertainties or other
factors. The Company undertakes no obligation to update or revise such
statements or the factors which may relate thereto.
OVERVIEW
CPI is a development stage pharmaceutical company focused on the
research, development and commercialization of products to prevent and treat
cancer. From the inception of the Company's business in 1990, operating
activities have related primarily to conducting research and development,
raising capital and recruiting personnel. The Company's initial investigational
new drug application ("IND") was filed with the Food and Drug Administration
("FDA") in December 1993 for human clinical trials of the Company's first
product candidate, Aptosyn(TM). The Company filed an IND for its second product
candidate, CP 461, in December 1998. In August 1999, the Company submitted to
the FDA an NDA for Aptosyn(TM) for FAP, a FDA designated orphan drug indication.
The Company is continuing to conduct clinical trials of Aptosyn(TM) and CP 461
for the prevention and treatment of various precancer and cancer indications.
On November 3, 1998, CPI completed a financing through the acquisition
of Tseng Labs, Inc. ("Tseng") (a publicly-held company with no continuing
operations which, subsequent to the transaction, became a subsidiary of CPI), in
which CPI issued to Tseng stockholders approximately 5.5 million shares of CPI
Common Stock and received net proceeds of approximately $26.4 million. In
October 1999, the Company issued 1.555 million shares of Common Stock for net
proceeds of approximately $13.5 million. This increased the Common Stock
outstanding to 26.1 million shares. During the six months ended June 30, 2000,
the Company received approximately $17.3 million primarily from the exercise of
previously issued Common Stock warrants and options. This increased the Common
Stock outstanding to 27.6 million shares.
9
<PAGE> 10
The Company has not received any revenue from the sale of products, and
no product candidate of CPI has been approved for marketing. CPI's income has
been limited to interest income from investments, and CPI's primary source of
capital has been the sale of its equity securities, including the transaction
with Tseng. Annual losses were $19,633,722 and $19,345,436 in 1999 and 1998,
respectively. As of June 30, 2000, CPI's accumulated deficit was $78,654,177 and
its unrestricted cash and cash equivalents were $35,467,645. CPI anticipates
that it will continue to incur additional operating losses for the next several
years. There can be no assurance that any of CPI's product candidates will be
approved for marketing, that CPI will attain profitability or, if profitability
is achieved, that CPI will remain profitable on a quarterly or annual basis in
the future. CPI's operating results will fluctuate from quarter to quarter. Some
of these fluctuations may be significant and, as a result, quarter to quarter
comparisons may not be meaningful.
RESULTS OF OPERATIONS
Three Months Ended June 30, 2000 Compared with Three Months Ended June 30,
1999. Total expenses for the three months ended June 30, 2000 were $7,693,467,
an increase of $3,035,373 or 65.2% from the same period in 1999. Research and
development expenses for the three months ended June 30, 2000 were $5,237,800,
an increase of $1,647,458 or 45.9%, from the three months ended June 30, 1999.
Such increase was primarily due to purchases of raw material of Apotsyn(TM) for
clinical supplies and in preparation for the production of commercial product.
General and administrative expenses were $2,455,667 for the three months ended
June 30, 2000, an increase of $1,387,915 or 130.0%, from the same period in
1999. Such increase was primarily due to expenses associated with preparations
for the commercialization of Aptosyn(TM).
Interest income was $539,756 for the three months ended June 30, 2000,
an increase of $214,373 or 65.9% from the same period of 1999 primarily due to
higher average cash balances.
Six Months Ended June 30, 2000 Compared with Six Months Ended June 30, 1999.
Total expenses for the six months ended June 30, 2000 were $14,704,640, an
increase of $4,374,109 or 42.3% from the same period in 1999. Research and
development expenses for the six months ended June 30, 2000 were $10,617,762, an
increase of $2,499,527 or 30.8%, from the six months ended June 30, 1999. Such
increase was due to purchases of raw material of Apotsyn(TM) for clinical
supplies and in preparation for the production of commercial product and a
non-cash charge of approximately $484,000 related to the estimated value of
stock options previously granted to scientific advisory board members, based
upon the Company's current stock price at June 30, 2000, which stock price had
increased substantially during the six months ended June 30, 2000. General and
administrative expenses were $4,086,878 for the six months ended June 30, 2000,
an increase of $1,874,582 or 84.7%, from the same period in 1999. Such increase
was primarily due to expenses associated with preparations for the
commercialization of Aptosyn(TM).
Interest income was $1,013,957 for the six months ended June 30, 2000,
an increase of $320,728 or 46.3% from the same period of 1999 primarily due to
higher average cash balances.
LIQUIDITY AND CAPITAL RESOURCES
CPI has financed its operations since inception primarily with the net
proceeds received from private placements of equity securities and the
transaction with Tseng. Financing activities have generated net proceeds of
$113,097,518 from inception through June 30, 2000. During the six months ended
June 30, 2000, the Company's cash from financing activities increased
$17,164,944, primarily as a result of the exercise of Common Stock warrants and
options.
At June 30, 2000, the Company had cash and cash equivalents of
$35,467,645, an increase of $3,454,527 from the cash and cash equivalent
position at December 31, 1999. Cash was used to finance the net loss of
$13,690,683 in the first six months of 2000. Such use of cash was offset by
approximately $17,164,944 from financing activities, principally the exercise of
Common Stock warrants and options as further described in Part II, Item 2.
Subsequent to June 30, 2000, the Company has received approximately $3,440,000
primarily from the exercise of warrants to purchase Common Stock. During the six
months ended June 30, 2000, the Company made advance payments of $1,089,688
towards future manufacturing expenses for Apotsyn(TM). CPI invests its excess
cash primarily in low risk, highly liquid money market funds and U.S. government
treasuries. CPI had $657,346 in a restricted account pledged as security for a
letter of credit for a security deposit under the lease of its Horsham,
Pennsylvania facility, and as security to a letter of credit for a portion of a
software lease commitment.
In July 2000, the Company signed a Master Loan and Security Agreement
("the Agreement") to provide financing for past and future equipment purchases.
The Agreement allows for the Company to borrow up to $2.0 million in various
10
<PAGE> 11
installments over a year period. Each installment is repayable over 48 months.
CPI leases approximately 40,000 square feet of laboratory and office
space in Horsham, Pennsylvania under a ten - year lease which expires in 2008
and which contains two five - year renewal options. The Company believes its
facilities will be adequate for the foreseeable future.
During the six months ended June 30, 2000 and 1999, the Company
acquired $380,697 and $300,862, respectively, in equipment, furniture and
leasehold improvements for its research laboratories and offices in its Horsham
facility.
CPI anticipates that quarterly and annual expenditures for preclinical
studies, clinical trials, product development, research, selling, marketing and
administrative expenses will increase significantly in future periods. In
anticipation of possible FDA approval of Aptosyn(TM) for FAP, the Company has
incurred commercialization expenses. Such expenses are expected to be
significant in 2000. There can be no assurance that CPI will be able to
successfully complete the clinical development of Aptosyn(TM) for FAP or any
other indication, that the FDA will grant approval within the time frame
expected, if at all, that the other developments or expansions in CPI's
research, development and commercialization programs will not require additional
funding or encounter delays or that, in light of these or other circumstances,
CPI will be able to achieve anticipated levels of revenue, expense and cash
flow.
CPI cannot predict the date of its first product approval, if any, the
rate of revenue generated from initial product sales, if achieved, or the level
of expense which may be associated with such initial product sales. Accordingly,
the Company anticipates that it may require additional financing in the future
to continue its research and development programs. Absent sufficient revenue
from product sales, CPI plans to finance its anticipated growth and development
largely through equity or debt financing and/or strategic alliances with
corporate partners. CPI believes, based on its current operating plans, and
without benefit of any revenue from product sales if product approval is
achieved, that its existing cash and cash equivalents balance of approximately
$35.5 million as of June 30, 2000, together with interest earned on these
balances, will provide sufficient working capital to sustain operations into the
second half of 2001. However, there can be no assurance the Company will not
require additional funding prior to that time, as the Company must adapt to
changing circumstances arising from within the Company's programs or from
outside the Company. There can be no assurance that additional equity or debt
financing or corporate collaborations will be available on terms acceptable to
CPI, if at all. Any additional equity financing would be dilutive to
stockholders. Debt financing, if available, may include restrictive covenants.
Corporate alliances could require the Company to give up certain marketing
rights or other rights to its potential products and technology. If additional
funds should be needed but are not available, CPI may be required to modify its
operations significantly or to obtain funds by entering into collaborative
arrangements or other arrangements on unfavorable terms. The failure by CPI to
raise capital on acceptable terms if and when needed would have a material
adverse effect on CPI's business, financial condition and results of operations.
INFLATION
The Company does not believe that inflation has had any significant
impact on its business to date.
INCOME TAXES
As of June 30, 2000, CPI has net operating loss carryforwards ("NOLs")
for income tax purposes available to offset future federal income tax, subject
to limitations for alternative minimum tax. In addition, the Company has other
significant deferred tax assets that will also offset future income tax. As the
Company has not yet achieved profitable operations, management believes the tax
assets do not satisfy the realization criteria of Statement of Financial
Accounting Standards No. 109 "Accounting for Income Taxes" and therefore the
Company has recorded a valuation allowance for the entire amount of its net tax
asset as of June 30, 2000. (Also see Note 11 of notes to consolidated financial
statements in the Company's annual report on Form 10-K.)
The Tax Reform Act of 1986 contains provisions that may limit the NOLs
available to be used in any given year upon the occurrence of certain events,
including significant changes in ownership interest. A change in ownership of a
company greater than 50% within a three-year period results in an annual
limitation on CPI's ability to utilize its NOLs from tax periods prior to the
ownership change. The Company believes that the transaction with Tseng triggered
such limitation. However, the Company does not expect such limitation to have a
significant impact on its operations.
11
<PAGE> 12
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
INTEREST RATE RISK
The Company's exposure to market risk for changes in interest rates
primarily relates to the Company's investment portfolio. The Company is averse
to principal loss and seeks to limit default risk, market risk and reinvestment
risk. In particular, the Company does not use derivative financial instruments
in its investment portfolio, places its investments with high quality issuers
and, except for investments with the U.S. Government, limits the amount of
credit exposure to any one issuer. The Company mitigates default risk by
investing in only the safest and highest credit quality securities,
predominantly those of the U.S. Government, and by positioning its portfolio to
respond appropriately to a significant reduction in a credit rating of any
investment issuer, guarantor or depository. The portfolio includes only
marketable securities with active secondary or resale markets to ensure
portfolio liquidity and has historically been invested in securities which have
original maturities of less than three months to ensure principal preservation.
As of June 30, 2000 and 1999, the Company was primarily invested in U.S.
Government securities and money market funds, which were classified as cash and
cash equivalents and restricted cash (included in other assets) in the Company's
financial statements. The investments had principal (or notional) amounts of
$36,731,934 and $28,585,599, respectively, which were equal to their fair value,
average interest rates of 5.4% and 4.3%, respectively, and maturities of less
than three months.
12
<PAGE> 13
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The information set forth in Footnote 3 to the notes to the Company's
condensed consolidated financial statements included herein is hereby
incorporated by reference.
ITEM 2. CHANGE IN SECURITIES AND USE OF PROCEEDS
During the three months ended June 30, 2000, the Company issued 35,147
shares of Common Stock for $166,948 pursuant to the exercise of previously
outstanding warrants issued in 1998; 30,821 shares of Common Stock for $431,494
pursuant to the exercise of previously outstanding warrants issued in 1999; and,
as part of the placement fee in connection with the financing previously
reported on Form 10-Q for the third quarter of 1999, a warrant for 179 shares of
Common Stock exercisable at $14 per share; all pursuant to the exemption
provided by Section 4(2) of the Securities Act. The Company plans to use the
proceeds from the aforementioned exercises of warrants to support the
development of Aptosyn(TM), to support the Company's research and development
programs and for general corporate needs.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At the Annual Meeting of Stockholders held on May 31, 2000, the following
matters were submitted to a vote of security holders:
a) Three directors were elected for terms of three years each, as follows:
<TABLE>
<CAPTION>
Votes Votes Votes % of Outstanding
Director FOR AGAINST WITHHELD Voting FOR
-------- ----- ------- -------- ----------------
<S> <C> <C> <C> <C>
William A. Boeger 24,118,087 -- 284,516 87.68%
John J. Gibbons 24,116,515 -- 286,088 87.68%
Randall M. Toig 24,121,780 -- 280,823 87.69%
</TABLE>
b) Approval of an amendment to the 1997 Equity Incentive Plan ("the Plan") to
increase the authorized number of shares of the Common Stock which may be
issued or made subject of awards under the Plan by 3,250,000 to a total of
5,600,000, including all shares authorized since the inception of the Plan
in 1993.
The stockholders approved the amendment to the Plan by a vote of 14,528,920
in favor, 1,091,263 against, 129,976 abstentions and 8,652,444 broker
non-votes.
c) Adoption of an amendment to the Certificate of Incorporation to increase the
total number of shares of stock the Company is authorized to issue to
160,000,000 shares, consisting of 150,000,000 shares of Common Stock and
10,000,000 shares of Preferred Stock with each class of stock having a par
value of $0.01.
The stockholders adopted the amendment to the Certificate of Incorporation
by a vote of 14,653,878 in favor, 960,535 against, 127,097 abstentions and
8,661,093 broker non- votes.
d) Ratification of the selection of Arthur Andersen LLP as independent auditors
of the Company for 2000.
The stockholders ratified the selection of Arthur Andersen LLP as independent
auditors of the Company by a vote of 24,222,828 in favor, 127,089 against and
52,686 abstentions.
13
<PAGE> 14
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) The following is a list of exhibits filed as part of the Form 10-Q.
3.1 Certificate of Incorporation as amended November 2, 1998.
3.2 Amendment to Certificate of Incorporation by way of Certificate of
Designation, Preferences and Rights of Series A Junior Participating
Preferred Stock as amended December 15, 1998.
3.3 Amendment to the Certificate of Incorporation as amended June 6,
2000.
10.3 1997 Equity Incentive Plan of Cell Pathways, Inc. as
amended May 31, 2000.
27.1 Financial Data Schedule, which is submitted electronically to the
Securities and Exchange Commission for information only, and not filed.
(b) There were no reports on Form 8-K filed during the quarter ending June
30, 2000.
14
<PAGE> 15
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CELL PATHWAYS, INC.
Dated: August 2, 2000 By: /s/ Robert J. Towarnicki
-----------------------------
Robert J. Towarnicki
President, Chief Executive Officer and
Director (Principal Executive Officer)
Dated: August 2, 2000 By: /s/ Brian J. Hayden
-----------------------------
Brian J. Hayden
Chief Financial Officer; Vice President -
Finance; Treasurer (Principal Financial and
Accounting Officer)
